Explore the latest news from Khondrion and its team.
Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.
Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical...
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical...
THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial...
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes...
Primary Mitochondrial Diseases (PMDs) are a group of conditions that usually affect multiple organs and systems in the body. They are caused by problems in the mitochondria—the parts of our cells that produce energy...
Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just...
Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside...
2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress achieved by Khondrion in its...
How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a very exciting time, two months...
How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I first learnt of mitochondrial...
